212 related articles for article (PubMed ID: 26160441)
1. Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis.
Juarez M; Bang H; Hammar F; Reimer U; Dyke B; Sahbudin I; Buckley CD; Fisher B; Filer A; Raza K
Ann Rheum Dis; 2016 Jun; 75(6):1099-107. PubMed ID: 26160441
[TBL] [Abstract][Full Text] [Related]
2. Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid Arthritis.
Challener GJ; Jones JD; Pelzek AJ; Hamilton BJ; Boire G; de Brum-Fernandes AJ; Masetto A; Carrier N; Ménard HA; Silverman GJ; Rigby WFC
J Rheumatol; 2016 Feb; 43(2):273-281. PubMed ID: 26669911
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
4. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
[TBL] [Abstract][Full Text] [Related]
5. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
[TBL] [Abstract][Full Text] [Related]
7. Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients.
Martínez G; Gómez JA; Bang H; Martínez-Gamboa L; Roggenbuck D; Burmester GR; Torres B; Prada D; Feist E
Rheumatol Int; 2016 Jun; 36(6):781-91. PubMed ID: 27038800
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
[TBL] [Abstract][Full Text] [Related]
9. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.
van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D
Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716
[TBL] [Abstract][Full Text] [Related]
10. Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.
Kastbom A; Forslind K; Ernestam S; Geborek P; Karlsson JA; Petersson IF; Saevarsdottir S; Klareskog L; van Vollenhoven RF; Lundberg K
Ann Rheum Dis; 2016 Feb; 75(2):356-61. PubMed ID: 25550338
[TBL] [Abstract][Full Text] [Related]
11. Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.
Koivula MK; Heliövaara M; Rissanen H; Palosuo T; Knekt P; Immonen H; Risteli J
Ann Rheum Dis; 2012 Oct; 71(10):1666-70. PubMed ID: 22419777
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
[TBL] [Abstract][Full Text] [Related]
13. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
Zhu T; Feng L
Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
Maraina CH; Nurdayana AK; Rusni D; Azwany Y
Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
[TBL] [Abstract][Full Text] [Related]
15. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
[TBL] [Abstract][Full Text] [Related]
16. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
17. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
[TBL] [Abstract][Full Text] [Related]
19. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
[TBL] [Abstract][Full Text] [Related]
20. Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis.
Schwenzer A; Jiang X; Mikuls TR; Payne JB; Sayles HR; Quirke AM; Kessler BM; Fischer R; Venables PJ; Lundberg K; Midwood KS
Ann Rheum Dis; 2016 Oct; 75(10):1876-83. PubMed ID: 26659718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
